论文部分内容阅读
目的观察依达拉奉对急性脑出血的临床疗效。方法将189例急性脑出血患者随机分成治疗组96例和对照组93例。治疗组在常规治疗的基础上,给予依达拉奉30 mg+生理盐水100 ml静脉滴注,30 min内滴完,每日2次,共14 d。治疗前及治疗后14 d分别进行神经功能缺损评分及疗效评定。结果治疗14 d后,治疗组治疗后神经功能缺损评分为(11±7)分,明显低于对照组(17±8)分(P<0.05);治疗组显效率和有效率分别为50.0%和87.5%,显著高于对照组的22.6%和61.3%(P<0.05)。结论依达拉奉治疗急性脑出血是安全有效的。
Objective To observe the clinical efficacy of edaravone on acute cerebral hemorrhage. Methods A total of 189 patients with acute cerebral hemorrhage were randomly divided into treatment group (96 cases) and control group (93 cases). On the basis of routine treatment, the treatment group was given edaravone 30 mg + saline 100 ml intravenously, drip finished within 30 min twice daily for 14 days. Before treatment and 14 d after treatment, neurological deficit score and curative effect were evaluated respectively. Results After 14 days of treatment, the score of neurological deficit in the treatment group was (11 ± 7) points, which was significantly lower than that of the control group (17 ± 8) (P <0.05). The effective rate and effective rate in the treatment group were 50.0% And 87.5% respectively, which was significantly higher than 22.6% and 61.3% (P <0.05) of the control group. Conclusion Edaravone in the treatment of acute cerebral hemorrhage is safe and effective.